Gensight Biologics SA
PAR:SIGHT

Watchlist Manager
Gensight Biologics SA Logo
Gensight Biologics SA
PAR:SIGHT
Watchlist
Price: 0.2765 EUR -0.36%
Market Cap: 32m EUR
Have any thoughts about
Gensight Biologics SA?
Write Note

Gensight Biologics SA
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Gensight Biologics SA
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Gensight Biologics SA
PAR:SIGHT
Revenue
€2.4m
CAGR 3-Years
-37%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Valneva SE
PAR:VLA
Revenue
€229.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Innate Pharma SA
PAR:IPH
Revenue
€24.9m
CAGR 3-Years
-10%
CAGR 5-Years
-26%
CAGR 10-Years
11%
G
Genfit SA
PAR:GNFT
Revenue
€84m
CAGR 3-Years
151%
CAGR 5-Years
61%
CAGR 10-Years
29%
Inventiva SA
PAR:IVA
Revenue
€15.6m
CAGR 3-Years
255%
CAGR 5-Years
37%
CAGR 10-Years
N/A
Eurobio Scientific SA
PAR:ALERS
Revenue
€144.2m
CAGR 3-Years
-13%
CAGR 5-Years
21%
CAGR 10-Years
17%
No Stocks Found

Gensight Biologics SA
Glance View

Market Cap
32m EUR
Industry
Biotechnology

GenSight Biologics SA is a clinical-stage gene therapy company. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2016-07-13. The firm develops and commercializes gene therapy-based treatments of retinal degenerative diseases. The company develops approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from low vision or blindness. The firm intends notably to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP).

SIGHT Intrinsic Value
0.1634 EUR
Overvaluation 41%
Intrinsic Value
Price

See Also

What is Gensight Biologics SA's Revenue?
Revenue
2.4m EUR

Based on the financial report for Jun 30, 2024, Gensight Biologics SA's Revenue amounts to 2.4m EUR.

What is Gensight Biologics SA's Revenue growth rate?
Revenue CAGR 3Y
-37%

Over the last year, the Revenue growth was -43%. The average annual Revenue growth rates for Gensight Biologics SA have been -37% over the past three years .

Back to Top